Nine months after multiple biosimilar rivals to Humira (adalimumab) launched in the US, the immediate shape of competition to the once top-selling immunology brand is clear. Biosimilars struggled to capture meaningful market share in 2023, together accounting for just 2% of the market by the end of the year (see sidebar).
Leading The Charge On US Humira Competition, Organon Sets Out Strategy
US Biosimilars Head Jon Martin Talks Adalimumab And Further Opportunities Beyond
With US biosimilar competition to Humira slow to start in 2023, Organon’s US biosimilars head Jon Martin talks about how the firm is pushing forward to ramp up progress on adalimumab this year, as well as longer-term opportunities.
More from Biosimilars
More from Products
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.